Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

ClinicalTrials.gov ID: NCT03281876

Public ClinicalTrials.gov record NCT03281876. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients

Study identification

NCT ID
NCT03281876
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
606 participants

Conditions and interventions

Interventions

  • NTHi Mcat investigational vaccine (GSK3277511A) Biological
  • Placebo Biological

Biological

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 26, 2017
Primary completion
Mar 25, 2020
Completion
Mar 25, 2020
Last update posted
Jan 10, 2021

2017 – 2020

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
23
Facility City State ZIP Site status
GSK Investigational Site Mesa Arizona 85213
GSK Investigational Site Phoenix Arizona 85018
GSK Investigational Site Phoenix Arizona 85020
GSK Investigational Site Palm Springs California 92262
GSK Investigational Site Clearwater Florida 33765
GSK Investigational Site Jacksonville Florida 32205
GSK Investigational Site Jacksonville Florida 32216
GSK Investigational Site Council Bluffs Iowa 51503
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Missoula Montana 59808
GSK Investigational Site Neptune City New Jersey 07753
GSK Investigational Site Charlotte North Carolina 28207
GSK Investigational Site Mooresville North Carolina 28117
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Columbus Ohio 43213
GSK Investigational Site Corvallis Oregon 97330
GSK Investigational Site Medford Oregon 97504
GSK Investigational Site Erie Pennsylvania 16508
GSK Investigational Site Gaffney South Carolina 29340
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Union South Carolina 29379
GSK Investigational Site Abingdon Virginia 24210
GSK Investigational Site Richmond Virginia 23225
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03281876, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 10, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03281876 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →